DPP4 and chronic kidney disease: Our data demonstrate that the administration of the DPPIV inhibitor sitagliptin to rats subjected to a 5/6 renal ablation attenuates cardiac hypertrophy, interstitial fibrosis and diastolic dysfunction, suggesting that the DPPIV inhibitors can attenuate the progression of CVD in the setting of CKD.